1.	Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LTS12674, 2011-006246-33, U1111-1127-0888, NCT01593228
2.	Phase I/II Study of Iniparib and Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed Malignant Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: ABTC-0703, NABTT-0703, NABTT-0703, NCT00589576
3.	A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TED11746, U1111-1118-6091, NCT01455532
4.	A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases Phase: Phase I Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: RAPIBE, 2011-003772-36, NCT01551680